Life Technologies Corporation sequence-based system for HLA typing

Life Technologies Corporation has received US Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore HLA typing kits. The Applied Biosystems 3500 Dx/3500xL Dx CS2 Genetic Analyzers, Invitrogen SeCore HLA Sequencing Kits and uTYPE Dx HLA Sequence Analysis Software constitute the first 510(k)-cleared, sequence-based system for HLA typing in the United States.

Tissue typing is an essential component of determining compatibility between donors and patients for organ and bone marrow transplantation. HLA typing on the 3500 Dx offers labs an optimised, streamlined workflow said to have higher resolution than other molecular HLA typing technologies such as sequence-specific oligonucleotide (SSO) methods.